Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has Magic Formula Rank of 5057. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to bring to light high quality companies that are trading at a price attractive to investors. The formula combines ROIC and earnings yield ratios to find solid, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.
Investors may be trying to define which trends will prevail in the second half of the year. As the markets continue to chug along, investors may be trying to maximize gains and become better positioned for success. Technical analysts may be surveying alternate historical price and volume data in order to assist bring to light where the momentum is headed. Coming up with a solid strategy may take some time, but it might be well worth it in the long run. As we move deeper into the year, investors will be closely tracking the next few earnings periods. They may be trying to project which companies will post positive surprises.
Checking in on some valuation rankings, Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has a Value Composite score of 55. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a enterprise with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued enterprise. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is at present sitting at 44.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has a Price to Book ratio of 2.463181. This ratio is determined by dividing the current stock price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some different ratios, the enterprise has a Price to Cash Flow ratio of 40.373121, and a current Price to Earnings ratio of -25.844499. The P/E ratio is one of the most common ratios used for figuring out whether a enterprise is overvalued or undervalued.
Shifting gears, we can see that Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has a Q.i. Value of 43.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to assist identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the enterprise tends to be.
Watching some historical volatility numbers on shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX), we can see that the 12 month volatility is right now 0.000000. The 6 month volatility is 42.077300, and the 3 month is spotted at 42.614900. Following volatility data can assist add up how much the equity price has fluctuated over the specified time timeframe. Although past volatility action may assist project future stock volatility, it may also be vastly alternate when taking into account different factors that may be driving price action during the measured time timeframe.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
At the time of writing, Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has a Piotroski F-Score of 2. The F-Score may assist detect companies with strengthening balance sheets. The score may also be used to bring to light the weak performers. Joseph Piotroski developed the F-Score which employs nine alternate variables based on the enterprise financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the different end, a stock with a score from 0-2 would be viewed as weak.
Investors may be interested in considering the Gross Margin score on shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX). The name at present has a score of 50.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.
The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a enterprise through a combination of dividends, share repurchases and debt reduction. The Shareholder Yield of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is 0.056173. This percentage is determined by adding the dividend yield plus the percentage of shares repurchased. Dividends are a common way that companies distribute cash to their shareholders. Similarly, cash repurchases and a reduction of debt can boost the shareholder value, too. Another way to figure out the effectiveness of a enterprise’s distributions is by studying at the Shareholder yield (Mebane Faber). The Shareholder Yield (Mebane Faber) of Amneal Pharmaceuticals, Inc. NYSE:AMRX is . This number is determined by studying at the measure of the dividend yield plus percentage of sales repurchased and net debt repaid yield.
Price Index
We can now take a quick peek at some historical equity price index data. Amneal Pharmaceuticals, Inc. (NYSE:AMRX) right now has a 10 month price index of 1.17988. The price index is determined by dividing the current stock price by the stock price ten months ago. A ratio over one suggests an boost in stock price over the timeframe. A ratio lower than one implies that the price has decreased over that time timeframe. Looking at some other time periods, the 12 month price index is 1.17988, the 24 month is 1.17988, and the 36 month is 1.17988. Narrowing in a bit closer, the 5 month price index is 1.07268, the 3 month is 0.75362, and the 1 month is at present 0.90036.
Stock market investors Often times rely on fundamental analysis for stock homework. The earnings per share or EPS ratio implies the amount of enterprise earnings that can be attributed to every share that is held. earnings per share lets investors directly compare one enterprise to another when examining potential investments. Investors are typically searching for stocks that have a growing earnings per share. The earnings per share add up tends to be more telling when viewed over a longer timeframe of time. When companies report quarterly earnings, the earnings per share add up is highly scrutinized by investors and analysts alike.
